EG 008
Alternative Names: EG-008Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Evergreen Therapeutics
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dry eyes
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in Dry-eyes in China (Ophthalmic, Drops)
- 23 Oct 2020 Shenzhen Eglin Pharmaceutical has patent protection for EG 008 (Shenzhen Eglin Pharmaceutical pipeline, October 2020)
- 23 Oct 2020 Preclinical trials in Dry eyes in China (Ophthalmic) (Shenzhen Eglin Pharmaceutical pipeline, October 2020)